INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY
AssigneeKaohsiung Medical University
InventorIng-Jun CHEN
Life of this patent
Estimating the term…
Abstract
A method for treating a disease is disclosed. The method includes steps of providing a subject in need thereof; and administering one selected from a group consisting of Piperazinyl Analogs and Piperazinyl Complex Analogs compound represented by formula II or formula III, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage between 1 and 5.0 milligrams per kilogram of body weight, in a liquid mist, dry powder or aerosolized formulation.
Claims20
A method for inhibiting a pulmonary inflammation, comprising steps of:
- providing a subject in need thereof;
- and
- administering a pharmaceutical composition of a KMUPs complex compound selected from a group consisting of KMUPs-RX complex compound, KMUPs-RX-RX complex compound and administer to the subject a dosage between 1 and 5.0 milligrams per kilogram of body weight,
- wherein KMUPs include KMUP-1, KMUP-2, KMUP-3 and KMUP-4:
- RX includes a carboxylic group selected from a group consisting of a Statin analogue, a Co-polymer, a poly-γ-polyglutamic acid derivative, ascorbic acid, an oleic acid, a phosphoric acid, a citric acid, a nicotinic acid and a sodium CMC;
- and
- the pulmonary inflammation comprises one selected from a group consisting of a pulmonary artery hypertension, a pulmonary artery proliferation, an allergic pulmonary vascular inflammation, a physiological activity of a lung cell, a vascular remodeling inhibiting disease and a combination thereof.
A combination method for inhibiting a pulmonary inflammation, comprising steps of:
- providing a subject suffering from the pulmonary inflammation;
- and
- administering a combination of one selected from a group consisting of Piperazinyl Analogs compounds, and administrating a pharmaceutically effective amount of a compound selected from a group consisting of Statin analogue, a Co-polymer, a poly-γ-polyglutamic acid derivative, ascorbic acid, an oleic acid, a phosphoric acid, a citric acid, a nicotinic acid and a sodium CMC, thereof to the subject in need thereof in a combination dosage between 1 and 5.0 milligrams per kilogram of body weight.
Dependencies are inferred from the claim text.